Jerome Kim, M.D., is the Director General of the International Vaccine Institute (IVI) and an international expert on the evaluation and development of vaccines. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma, is completing Phase III testing. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19 vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis ,in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army’s Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 250 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
